预约演示
更新于：2025-08-17
AstraZeneca PLC
更新于：2025-08-17
概览
标签
肿瘤
呼吸系统疾病
泌尿生殖系统疾病
小分子化药
单克隆抗体
ADC
疾病领域得分
一眼洞穿机构专注的疾病领域
技术平台
公司药物应用最多的技术
靶点
公司最常开发的靶点
关联
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
NCT07049653
A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data From Women With SLE Exposed to Anifrolumab
NCT06927648
CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA
NCT05403723
A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer
100 项与 AstraZeneca PLC 相关的临床结果
登录后查看更多信息
登录后查看更多信息
2025-12-31Human Vaccines & Immunotherapeutics
Exploring nurses’ experiences with a school-located influenza vaccination program: A qualitative study in the region of Murcia, Spain
Article
作者: Perez Martin, Jaime ; Robles Mañueco, Marta ; Martínez Ruiz, Marina ; Zornoza Moreno, Matilde
A cross-sectional qualitative pilot study was designed to assess the nurses' perspectives regarding a school-located influenza vaccination pilot program. The program was developed during the 2022-2023 season in the Region of Murcia (an autonomous community of Spain) targeting the 3- to 4-year population in 24 public schools, using the intranasal Fluenz® Tetra vaccine. School nurses unanimously recognized their professional role not only in administering the vaccine, but also in the development and implementation of general aspects of the pilot program and reported that the experience was very positive. Nursing professionals should be fully involved in providing information to parents about the main aspects of influenza infection and benefits of having their children vaccinated against seasonal influenza. Nurses also advocated that the flu vaccination for children should begin at the same time as vaccination for adults, with vaccination planning completely integrated into the school schedule.Practice implications: The study results could guide healthcare authorities in facilitating the implementation of school-located influenza vaccination programs and increase immunization of preschool children against flu.
2025-10-01Multiple Sclerosis and Related Disorders
ACT with NMOSD: A targeted, telehealth-delivered mental health intervention for patients & caregivers
Article
作者: Nurse, Chelsi N ; Wakschal, Emily ; Peppers, Charles L ; Deshpande, Ankita ; Esiason, Darcy C ; Erler, Wendy ; Andrews, Leigh ; Levy, Michael ; Hattrich, Tom ; O'Hayer, C Virginia ; Bruschwein, Heather ; Leist, Thomas ; Kushner, Hallie M ; Smith, Patrick J ; Drescher, Christopher F
PURPOSE:
The rare, unpredictable, debilitating nature of neuromyelitis optica spectrum disorder (NMOSD) constitutes a unique psychological burden. This single-arm, pilot clinical trial examined the effectiveness of Acceptance and Commitment Therapy (ACT) tailored to meet the psychological burden of NMOSD, a brief telehealth-delivered intervention, targeting this burden.
METHODS:
Forty-three adults with NMOSD (76 % aquaporin-4 seropositive (AQP4+)) in USA, with elevated anxiety and/or depression completed 6-weeks of an experiential talk therapy designed to increase psychological flexibility and valued action, specifically tailored to address the psychological burden of NMOSD: Acceptance and Commitment Therapy (ACT) w NMOSD. Patients attended via Zoom, along with 22 caregivers, providing baseline, posttreatment, and follow-up measures of depression, anxiety, cognitive fusion, psychological flexibility, valued living, disability, sleep, fatigue, and pain. Linear mixed effect models examined changes in repeated measures of all outcomes, controlling for age, sex, disability, AQP4 serostatus.
RESULTS:
Participants were mostly female (84 %) and Caucasian (56 %), with baseline mild depression (mean 15.4 [SD = 8.7]) and moderate anxiety (mean = 13.5 [SD = 9.3]). Most participants (93 %) completed all treatment sessions and study assessments. Pre-to-post treatment analysis showed clinically meaningful reductions in depression (15.4 (12.8, 19.0) to 11.1 (8.3, 13.8) P<.001;) and anxiety (13.5 (11.2, 15.7) to 10.0 (7.5, 12.4) P ≤.005). Parallel improvements in cognitive fusion (39.6 (35.6, 43.6) to 33.7 (29.6, 37.7) P<.001), psychological acceptance (20.0 (17.3, 22.8) to 17.0 (14.2, 19.8) P < 0.002), valued living (49.2 (43.2, 55.3) to 60.5 (54.4, 66.6) P<.001), and sleep quality (10.1 (9.0, 11.2) to 8.3 (7.1, 9.5), P<.001) support the overall benefit of ACT to mental health. Improvements remained at 3-month follow-up. Disability status, pain, fatigue, were unchanged, as expected.
CONCLUSIONS:
ACT with NMOSD is a promising innovative targeted mental health intervention for adults with NMOSD with lasting benefits.
CLINICALTRIALS:
gov ID # NCT05840055 Supported by Alexion Pharmaceuticals.
2025-08-01Journal of Allergy and Clinical Immunology-In Practice
Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data
Article
BACKGROUND:
For severe asthma (SA) management, real-world evidence on the effects of biologic therapies in reducing the burden of oral corticosteroid (OCS) use is limited.
OBJECTIVE:
To estimate the efficacy of biologic initiation on total OCS (TOCS) exposure in patients with SA from real-world specialist and primary care settings.
METHODS:
From the International Severe Asthma Registry (ISAR, specialist care) and the Optimum Patient Care Research Database (OPCRD, primary care, United Kingdom), adult biologic initiators were identified and propensity score-matched with non-initiators (ISAR, 1:1; OPCRD, 1:2). The impact of biologic initiation on TOCS (including bursts for exacerbations) daily dose in the first- and second-year follow-up period was estimated using multivariable generalized linear models.
RESULTS:
Among 5,663 patients (ISAR 48%, OPCRD 52%), the odds ratios (ORs) of biologic initiators achieving TOCS cessation in the first and second years of follow-up were 2.38 (95% CI, 1.87-3.04) and 2.11 (95% CI, 1.65-2.70), whereas the ORs of low (0- to 5-mg) TOCS intake were 1.62 (95% CI, 1.40-1.86) and 1.40 (95% CI, 1.21-1.61), respectively. Compared with non-initiators, biologic initiators had a substantially higher chance of achieving greater than 75% reduction from baseline (OR [95% CI] = 2.35 [2.06-2.68] and 1.53 [1.35-1.73] in first and second years, respectively). These findings remained persistent and robust when analyses were repeated with one country setting removed at a time.
CONCLUSIONS:
Biologic initiation in patients with SA led to substantial reduction in TOCS exposure, particularly in the first year. Future analyses will explore the impact on OCS-related adverse health events.
100 项与 AstraZeneca PLC 相关的药物交易
登录后查看更多信息
100 项与 AstraZeneca PLC 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2025年08月20日管线快照
管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期
药物发现
59
171
临床前
临床申请
3
54
临床1期
临床2期
89
38
临床3期
申请上市
3
81
批准上市
其他
812
登录后查看更多信息
当前项目
登录后查看更多信息
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用